secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001493152-25-003043
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech reports Q4 prelim net revenue up 45-48% YoY; FY up 32-33%
------------------------------------------------------------------------

- Q4 2024 net revenue expected $25.7M-$26.2M, a 45-48% increase YoY.
- Full year 2024 net revenue expected $86.0M-$86.5M, up 32-33% YoY.
- BIASURGE sales benefited from ~$1.8M in temporary demand due to hurricane-related IV fluid shortages; expects normalization in Q1 2025.
- Cash at Dec 31, 2024: $15.9M; debt $30.5M; $24.5M available borrowing capacity.
- Appointed Keith Myers (former LHC Group CEO) to Board on Oct 4, 2024; filed 11 provisional patent applications in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315225003043/0001493152-25-003043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315225003043/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-003043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer